Skip to main content

Durvalumab News (Page 2)

AstraZeneca’s Imfinzi (durvalumab) Receives FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer

May 1, 2017 – AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Endometrial Cancer, Hepatocellular Carcinoma

Durvalumab patient information at Drugs.com